GLP-1RA Alzheimer’s hopes dashed after Novo Nordisk’s semaglutide miss
While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the preventive Alzheimer’s setting.
25 November 2025
25 November 2025
While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the preventive Alzheimer’s setting.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.